<unk>  is a human interleukin-17 receptor A (IL-17RA) antagonist that is FDA approved for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include arthralgia, headache, fatigue, diarrhea, oropharyngeal pain, nausea, myalgia, injection site reactions, influenza, neutropenia, and tinea infections.
Brodalumab
Nebacumab
Evolocumab
Dupilumab
Ustekinumab
Sarilumab
Burosumab
Guselkumab